Quantification of Venlafaxine in Tablet Dosage Form

Quantification of Venlafaxine in knock backt Dosage FormNew chiral normal phase UFLC system for deter mination of venlafaxine hydrochloride enantiomers in pharmaceutic formulationsABSTRACTAim A simple, specific, precise, sensitive and rapid normal phase-UFLC regularity was positive for determination of venlafaxine hydrochloride enantiomers in pharmaceutical formulation.Methodology The system was developed on a Lux amylase 2 towboat (150 x 4.0 mm I.D., particle size 5 ) the mobile phase was n-hexane and fermentation alcohol (973 v/v) in 0.1%diethyamine using UV detector was fixed at 254 nm with a flow rate was 1 mL/min.Results The retention judgment of conviction (tR) of R- venlafaxine hydrochloride and S- venlafaxine hydrochloride were institute to be 4.50.2 min and 5.30.3 min, respectively. The li secretiveity over the concentration aim of 5-30 g mL-1 for venlafaxine. The intra-day and inter-day coefficient of variation of the assay method were found to be 0.293 to 1.760 and 0.319 to 0.210 respectively, with high accuracy and precision results. The proposed NP-UFLC method is suitable for analysis of venlafaxine hydrochloride enantiomers in pharmaceutical dosage forms.Conclusion The clear NP-UFLC method was developed for the quantification of venlafaxine in tablet dosage form.Keywords R-venlafaxine hydrochloride, S-venlafaxine hydrochloride, enantiomers, NP-UFLC, ValidationINTRODUCTIONVenlafaxine is a second-generation antidepressant dose marketed as a racemic variety show ( simulacrum 1). The R-enantiomer exhibits dual presynaptic inhibition of serotonin and noradrenaline uptake, whereas the S-enantiomer is a serotonine reuptake inhibitor. Thus, the dose is the root and approximately usually used serotonin and noradrenaline reuptake inhibitor. Its synthetic thinking and that of some(prenominal) analogues were described many years ago. The synthetic substance routes are similar and vary according to the nature of the aromatic substituents. H owever, the final products are racemic mixtures, and they were crystallized as hydrochlorides.1 Although the disposition of venlafaxine in humans was originally found not to be stereoselective.2 In view of the near expiration date (June 2008) of the first patent for the racemic compound and of these recent clinical findings, venlafaxine appears to be a bang-up candidate for a chiral switch.3-4Figure 1 Molecular structure of VenlafaxineThe trend toward single enantiomer doses is spend and the number of racemic drugs that reach the market as new chemical entities is decreasing.5 The relevance of chirality in antidepressant drugs was highlighted several years ago and many examples are illustrated in a recent very complete review.6-7 In the previously cited research on the resolution of venlafaxine, the enantiomers were separated by either of two general approaches. The first is the classical method of diastereoisomeric salt formation and fractional crystallization and the second ap proach uses analytical enantioselective electro compulsive methods. In the latter cases, either cyclodextrinsin capillary electrophoresis.8 There is only one literature report where an HPLC service line separation of the enantiomers of venlafaxine extracted was achieved using a CSP and normalphase mode.9 From an analytical point of view, enantioselective chromatography offers the advantages of a method that can be developed on a semipreparative or preparative scale for the isolation of single enantiomers, which then become useable for pharmaceutical testing strategies and requirements for enantioselective.10In the present research work, a simple, sensitive and accurate normal phase UFLC method to separate R and S-enantiomer of venlafaxine in bulk drugs and tablets using Lux amylase 2 tower column has been reported for first time. The method was also validated to ensure the compliance in accordance with the ICH guidelines.MATERIALS AND METHODSChemicals and ReagentsVenlafaxine hydroc hloride enantiomers were a gift sample from R N FINE CHEMICALS BANGALURU, India. The solvents like n-hexane and neutral spirits diethylamine used was of HPLC grade (Merck, India). commercially available racemic venlafaxine hydrochloride tablets claimed to contain 25mg of drug were procured from local market.InstrumentationQuantitative NP-UFLC was performed on gradient high force liquid chromatography (Shimadzu) auto sampler consisting of a LC20HT solvent module, SPD 10A, and an PDA detector with LC software. The column used was lux amylase 2 chiral column(150 x 4.0 mm ) particle size 5 .UFLC conditionsThe composition of the mobile phase was n-hexane and ethanol in the ratio of 9703 v/v. They were filtered before use through a 0.2 mm tissue layer filter, degassed in a bath sonicator for 10 min. The mobile phase was pumped from the solvent reservoir to the column at a flow rate of 1mL/min, which yielded a column backpressure of 96 kg/cm2. The run time was set at 20 min and column t emperature was ambient. The volume of injection loop was 20 mL. forward to injection of drug solutions, the column was equilibrated for at least 30 min with the mobile phase slick through the system. The eluents were monitored at 254 nm and data was acquired, stored and analyzed with the LC 10 software.REAGENTS USEDMobile phasen-hexane and ethanol of HPLC grade was taken as mobile phase in the ratio of 973 % (v/v). planning of essence stock solution shopworn stock solution (100 g mL-1) of Venlafaxine hydrochloride was prepared by deliberation exactly 10 mg of drug dissolved in isopropanol and diluted to 100 mL with same solvent.Preparation of calibration curveAliquots of Venlafaxine hydrochloride ranging from 0.5-3 mL (each mL contains 100 g mL-1) were pipetted into as a series of 10mL volumetric flasks. The volume was made up to the mark at with isopropanol. Aliquoets of 10L was injected (six time) into HPLC. The elution of the drug measured at 254.0 nm. The amount of venlafa xine hydrochloride present in the sample solution was computed from its calibration curve and it was constructed by plotting peak area of chromatogram against the concentration of Venlafaxine hydrochloride. The blank chromatogram and commonplace drug chromatogram were shown in figure 2 and 3 respectively. Linearity was 5.0-30 g mL-1 for Venlafaxine hydrochloride was shown in figure 4.Figure 2 Blank chromatogramFigure 3 Standard Chromatogram of venlafaxine enantiomerFigure 4 Calibration curve of venlafaxine hydrochlorideANALYSIS OF TABLET DOSAGE FORMtail fin tablets (EFFEROX), each containing 25 mg of venlafaxine hydrochloride were weighed and finely powdered. Powder equivalent to 125 mg of venlafaxine hydrochloride was weighed and transferred to a standard volumetric flask. The contents were mixed thoroughly and filtered through a 0.45 m membrane filter. 10 L of the sample was injected in to UFLC system for the analysis. The peak profile and peak purity of both enantiomers are show n in Fig. 5, 6, 7 and 8.Figure 5 visor Profile Enantiomer 1Figure 6 Peak Profile Enantiomer 2Figure 7 Peak Purity Enantiomer 1Figure 8 Peak Purity Enantiomer 2RESULTS AND DISCUSSIONValidation of the methodThe developed method for the assay of venlafaxine has been validated as per the current ICH Q2 (R1) guidelines.11Analytical parametersThe development of NP-UFLC method for the determination of enantiomers has received a considerable attention in recent past because of its importance in the flavor control of drugs and drug products. The assay of venlafaxine hydrochloride enantiomers was resolved with good accuracy. The retention time (tR) of R- venlafaxine hydrochloride and S- venlafaxine hydrochloride were found to be 4.50.2 min and 5.30.3 min, respectively. A representative chromatogram of R-Venlafaxine hydrochloride and S- venlafaxine hydrochloride is shown in Figure 3. Tailing factor for both R-venlafaxine hydrochloride and S-venlafaxine hydrochloride was found to be 1.1 and 0.8 respectively. The calibration curve was constructed by plotting the peak areas against the concentration of R-and S-venlafaxine hydrochloride in 5-30 g mL-1 were shown in the Figure 4. It was found to be linear with a correlation coefficient of 0.9971 for R-venlafaxine hydrochloride and 0.9992 for S-venlafaxine hydrochloride, the representative linear regression equation being y = 10507X +2467.1 and y = 10654X +2065.8 for both the enantiomers respectively. The slope, y-intercept, and their standard deviations evaluated are presented in Table 1.Table 1 Regression and sensitivity parameters of enantiomer-1 and enantiomer-2Accuracy and precisionThe amount of venlafaxine hydrochloride enantiomers in the matrix was calculated using next formula.% Recovery = T-A /S100T make out amount of drug estimated, A-initial amount of drug in the tablet powder and S- amount of pure drug added. The results revealed (Table 2), high recovery of Venlafaxine hydrochloride enantiomers, indicating that the proposed method for the determination of venlafaxine hydrochloride enantiomers in the tablet is highly accurate. The intraday and inter day function relative standard deviation values were shown in Table 3. These values were within the standard limits.Table 2 Accuracy data of enantiomer-1 and enantiomer-2Mean value of six determinationsTable 3 Precision data of enantiomer-1 and enantiomer-2Limit of detection and limit of quantificationLimit of detection can be calculated using the following equation according to ICH guidelines LOD = 3.3 x N/SLOQ = 10 x N/Swhere N is the standard deviation of peak areas of the drug and S is the slope of the corresponding calibration curve. The results are shown in Table 1.Assay of the drugThe chiral NP-HPLC method developed in the present investigation was used to mensurate venlafaxine hydrochloride enantiomers in tablet dosage forms. The obtained results are given in Tables 4. The average drug content was found to be 10.047 mg for R-venlafaxi ne hydrochloride and 9.978 mg for S-venlafaxine hydrochloride of the labelled amount in 25mg of racemic venlafaxine hydrochloride, respectively.Table 4 Assay of Venlafaxine hardiness of the method and stability of the solutionThe robustness of an analytical procedure has been defined by the ICH as a measure of its capacity to remain unaffected by small, but deliberate variations in method parameters. The most important aspect of robustness is to develop methods that develop methods that allow for expected variations in method parameters. accord to ICH guidelines, robustness should be considered early in the development stage of a method. The typical variations studied to a lower place this parameter are flow rate, wavelength and mobile phase composition. The results are tabulated in Table 5.Table 5 Robustness data of enantiomer-1 and enantiomer-2CONCLUSIONA simple, rapid and normal phase chiral UFLC method has been developed and validated for the enantiomeric separation of venlafa xine in tablet formulation. This method is precise, accurate, robust, and specific. Satisfactory results were obtained from the validation of the method. The short retention time (4.5 min for enantiomer 1 and 5.3 for enantiomer 2) obtained provides rapid determination of venlafaxine, which is significant for its routine analysis in quality control. The method exhibits an excellent performance in terms of sensitivity and robust. The experimental results of the present study showed that the proposed NP-UFLC method is simple, specific, precise, sensitive, rapid and accurate and is useful for separation of venlafaxine hydrochloride enantiomers in its pharmaceutical formulation.ReferencesYardley JP, Husbands GE, Stack G, Butch J, Bicksler J, Moyer JA, Muth EA, Andree T,Fletcher H, James MNG, Sielecki AR 2-Phenyl- 2-(1-hydroxycycloalkyl)ethylamine derivatives synthesis and antidepressant activity. J Med Chem 19903328992905.Wang CP, Howell SR, Scatina J, Sisenwine SF, The disposition of ve nlafaxineenantiomers in dogs, rats and humans receiving venlafaxine. Chirality 199248490.Ault A Big pharma is increasingly in getting a piece of the generic pie. The Scientist, 2005193638.Agranat I, Caner H, Caldwell J Putting chirality to work the strategy of chiral switches. Nat Rev Drug Discov 20021753768.Arina V, Reeves JT, Senanayake CH, Song JJ, Asymmetric synthesis of activepharmaceutical ingredients. Chem Rev 2006106 27342793.Ruffolo RR Chirality in and -adrenoceptor agonists and antagonists. Tetrahedron 19914799539980.Hutt AJ. Drug chirality and its pharmacological consequences. In Smith HJ, editor. intromission to the principles of drug design and action, 4th ed. Boca Raton CRC Press 2006. Pg no 117183.Fanali S, Cotichini V, Porra R Analysis of venlafaxine by capillary geographical zone electrophoresis. J Capillary Electrophor 199742126.Caccamese S, Biance S, Carter GT, Direct high performance liquid chromatography separation and 11 analogues using amylose derivated sta tionary phase, Chirality 2009 21 569-577.Anderson S. Preparative chiral chromatography. A powerful and efficient tool in drugdiscovery. In Subramanian G, editor. Chiral separation techniques, 3rd ed. Weinheim Wiley-VCH 2007. Pgno 585600.1